SCHEMBL1493219

SCHEMBL1493219

NCC(=O)N(CC(=O)O)C(=O)CS

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA1 P23415 1/20 0.38
SLC6A9 P48067 1/20 0.38
OR51E2 Q9H255 1/20 0.38
CPB2 Q96IY4 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
EYA2 O00167 1/20 0.32
APP P05067 1/20 0.32
ACE P12821 1/20 0.32
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
CHRM2 P08172 1/20 0.31
ADRA2A P08913 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
DRD1 P21728 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
CYP2C19 P33261 1/20 0.31
ADRA1A P35348 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL98566 0.89 GLRA1 (0.47) GLRA1SLC6A9OR51E2TDP1EYA2
SCHEMBL2819946 0.80 TERT (0.31)
SCHEMBL7872934 0.80
SCHEMBL28596943 0.79 GLRA1 (0.43) GLRA1SLC6A9OR51E2TDP1EYA2
SCHEMBL17633987 0.79
SCHEMBL27465344 0.78 TSHR (0.38) GLRA1SLC6A9OR51E2TDP1EYA2
SCHEMBL21955799 0.76 GLRA1 (0.39) GLRA1SLC6A9OR51E2TDP1EYA2
SCHEMBL10503057 0.76
SCHEMBL7594029 0.75 PTGS1 (0.42) GLRA1SLC6A9OR51E2CPB2
SCHEMBL28547740 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118785925-A Marker precursors and radiotracers with three or more targeting vectors for use in diagnostic nuclear medicine therapies 原子治疗有限公司 2024-10-15 CN claimed
CN-116710150-A Radiolabelled ether dendrimer conjugates for PET imaging and radiation therapy 阿什瓦塔治疗股份有限公司 2023-09-05 CN claimed
CN-116635408-A Reactive conjugates 德彪药业国际股份公司 2023-08-22 CN claimed
US-8575100-B2 Tc and Re labeled radioactive glycosylated octreotide derivatives MALLINCKRODT LLC (US) 2013-11-05 US claimed
US-7589061-B2 Tc and Re labeler radioactive glycosylated octreotide derivatives MALLINCKRODT INC. (US) 2009-09-15 US claimed
WO-2025125335-A1 CYTOTOXIC OR RADIOPHARMACEUTICAL COMPOUND WITH SULFUR FLUORIDE EXCHANGE GROUP RADIOVAXX GMBH (DE) 2025-06-19 WO disclosed
WO-2025125621-A1 CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS RADIOVAXX GMBH (DE) 2025-06-19 WO disclosed
CN-119053344-A Dendrimer compositions for targeted delivery of therapeutic agents to neurons 约翰霍普金斯大学 2024-11-29 CN disclosed
CN-118043482-A Methods for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a CCK2-R targeting compound, and compounds for use in methods for selectively treating and/or imaging cancer 保罗·谢勒学院 2024-05-14 CN disclosed
CN-117752825-A Pharmaceutical composition containing tag-anti-human antibody Fab fragment complex 安斯泰来制药株式会社 2024-03-26 CN disclosed
WO-2023222558-A1 PRECURSOR AND THERANOSTIC RADIOTRACER WITH IMPROVED TUMOR RETENTION ZOUNEK ALEXIS NIKOLAI (DE) 2023-11-23 WO disclosed
CN-112839683-B Pharmaceutical composition containing tag-anti-human antibody Fab fragment complex 安斯泰来制药株式会社 2023-11-14 CN disclosed
WO-2003076469-A9 ANTIBODIES DERIVED ROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE PHILOGEN SPA (IT) 2005-09-29 WO disclosed
CN-1639195-A Selective targeting of tumor vasculature using antibody molecules PHILOGEN SRL (IT) 2005-07-13 CN disclosed
EP-1548027-A1 COMPOUND BINDING TO LEUKOCYTES AND MEDICINAL COMPOSITION CONTAINING THE COMPOUND IN LABELED STATE AS THE ACTIVE INGREDIENT Nihon Medi-Physics Co., Ltd. (JP) 2005-06-29 EP disclosed
US-20050074401-A1 Selective targeting of tumor vasculature using radiolabelled antibody molecules SCHERING AG (DE) 2005-04-07 US disclosed
WO-2005023318-A1 TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B PHILOGEN S.P.A (IT) 2005-03-17 WO disclosed
EP-1514561-A1 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B Philogen S.p.A. (IT) 2005-03-16 EP disclosed
EP-1483297-A2 ANTIBODIES DERIVED FROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE Philogen S.p.A. (IT) 2004-12-08 EP disclosed
WO-2003076469-A2 ANTIBODIES DERIVED ROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE PHILOGEN S.P.A. (IT) 2003-09-18 WO disclosed